Compare
Medifast Inc vs Utz Brands, Inc. vs McCormick & Co Inc
| Latest fiscal year | Medifast Inc MED | Utz Brands, Inc. UTZ | McCormick & Co Inc MKC |
|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-28 | 2025-11-30 |
| Revenue | $385.79M | $1.44B | $6.84B |
| Revenue growth (YoY) | -36.0% | +2.1% | +1.7% |
| Gross margin | 71.3% | 24.9% | 37.9% |
| Operating margin | -3.7% | 1.4% | 15.7% |
| Net margin | -4.8% | 0.1% | 11.5% |
| Net income | -$18.67M | $800.0K | $789.40M |
| EPS (Diluted) | -$1.70 | $0.01 | $2.93 |
| Operating cash flow | $6.86M | $112.20M | $962.20M |
| Free cash flow | $1.25M | $9.40M | $740.40M |
| Cash & equivalents | $89.30M | $120.40M | $95.90M |
| Total assets | $247.97M | $2.79B | $13.20B |
| Total liabilities | $49.05M | $1.45B | $7.43B |
| Shareholders' equity | $198.92M | $713.70M | $5.77B |
| Return on year-end equity | -9.4% | 0.1% | 13.7% |
| Shares outstanding | 10.99M | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Medifast Inc | Utz Brands, Inc. | McCormick & Co Inc |
|---|---|---|---|
| Latest | $385.79M Ended 2025-12-31 | $1.44B Ended 2025-12-28 | $6.84B Ended 2025-11-30 |
| 1 year earlier | $602.46M Ended 2024-12-31 | $1.41B Ended 2024-12-29 | $6.72B Ended 2024-11-30 |
| 2 years earlier | $1.07B Ended 2023-12-31 | $1.44B Ended 2023-12-31 | $6.66B Ended 2023-11-30 |
| 3 years earlier | $1.60B Ended 2022-12-31 | $1.41B Ended 2023-01-01 | $6.35B Ended 2022-11-30 |
| 4 years earlier | $1.53B Ended 2021-12-31 | $1.18B Ended 2022-01-02 | $6.32B Ended 2021-11-30 |